DOI: https://doi.org/10.22263/2312-4156.2018.5.80
Sukonko O.G., Polyakov S.L., Rolevich A.I., Zhegalik A.G.
Treatment of musculo-invasive bladder cancer with poor prognosis: urgency of the problem
N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus
Vestnik VGMU. 2018;17(5):80-93.
Abstract.
Musculo-invasive bladder cancer with poor prognosis (рТ3-4N0 or pN+ category) is a very aggressive disease with high mortality rate. Nowadays complex treatment of this disease together with radical cystectomy includes neoadjuvant or adjuvant chemotherapy, mainly cisplatin-based one which is characterized by high toxicity and moderate efficacy. Proposed adjuvant chemotherapy regimens for musculo-invasive bladder cancer patients with no preoperative chemotherapy are ddM–VAC, GC or CMV. Recent researches data including also those of the prospective randomized study conducted by N.N. Alexandrov National Cancer Centre showed that adjuvant chemotherapy was the most effective in the subgroup of patients with no regional lymph nodes metastatic spreading.
Key words: musculo-invasive bladder cancer, cystectomy, adjuvant chemotherapy, neoadjuvant chemotherapy, survival.
References
1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun;27(3):289-93. doi: http://dx.doi.org/10.1007/s00345-009-0383-3
2. Okeanov AE, Moiseev PI, Levin LF, Polyakov SM, Yakimovich GV, Rubtsov SI, i dr; Sukonko OG, red. Statistics of cancer (2006-2015). Minsk, RB: RNPTs OMR im NN Aleksandrova; 2016. 279 р. (In Russ.)
3. Sukonko OG, Polyakov SL, Volkov AN, Rolevich AI, Mokhort AA. Ileocystoplasty after radical cystectomy for bladder cancer. Zdravookhranenie. 2004;(5):37-42. (In Russ.)
4. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001 Feb;19(3):666-75. doi: http://dx.doi.org/10.1200/JCO.2001.19.3.666
5. Walsh PC, Retik AB, Vaughan ED, Wein AJ. Campbell’s Urology. 8th ed. Philadelphia: Saunders Elsevier; 2002. Vol 3. 192 p.
6. Matveev BP, red. Clinical Oncourology. Moscow, RF; 2011. 934 р. (In Russ.)
7. Raghavan D. Progress in the chemotherapy of metastatic cancer of the urinary tract / D. Raghavan. 2003 Apr;97(8):2050-5. doi: http://dx.doi.org/10.1002/cncr.11280
8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug;349(9):859-66. doi: http://dx.doi.org/10.1056/NEJMoa022148
9. Stewart BW, Wild CP, eds. World Cancer Report 2014. Lyon, France: IARC Press; 2014. 630 p.
10. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009 Apr;55(4):815-25. doi: http://dx.doi.org/10.1016/j.eururo.2009.01.002
11. Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011 May-Jun;29(3):252-8. doi: http://dx.doi.org/10.1016/j.urolonc.2009.03.021
12. Miles BJ, Fairey AS, Eliasziw M, Estey EP, Venner P, Finch D, et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J. 2010 Aug;4(4):263-7.
13. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy wtih both preoperative and postoperative M-VAC. J Clin Oncol. 2001 Oct;19(20):4005-13.
14. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: prospective randomized phase III study. J Urol. 1995 Mar;153(3 Pt 2):964-73.
15. Orsatti M, Curotto A, Canobbio L, Guarneri D, Scarpati D, Venturini M, et al. Alternating chemoradiotherapy in bladder cancer: a conservative approach. Int J Radiot Oncol Biol Phys. 1995 Aug;33(1):173-8. doi: http://dx.doi.org/10.1016/0360-3016(95)00136-M
16. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996 Nov;14(11):2901-7. doi: http://dx.doi.org/10.1200/JCO.1996.14.11.2901
17. Bassi P, Pagano F, Pappagallo G, et al. Neo-adjuvant M-VAC chemotherapy of invasive bladder cancer: The GUONE multicenter phase III trial. Eur. Urol. 1998;33(Suppl 1):142.
18. GISTV (Italian Bladder Cancer Study Group). Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. J Chemother. 1993;29(Suppl 6):S229. doi: http://dx.doi.org/10.1016/0959-8049(93)91908-4
19. Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol. 1996 Jun;155(6):1903-6.
20. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. International collaboration of trialists. Lancet. 1999 Aug;354(9178):533-40.
21. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002;36(6):419-25.
22. Natale RB. SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant M-VAC and cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc Am Soc Clin Oncol. 2001;20, abstract 3.
23. Kitamura H, Tsukamoto T, Shibata T, Masumori N, Fujimoto H, Hirao Y, et al. Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209. Ann Oncol. 2014 Jun;25(6):1192-8. doi: http://dx.doi.org/10.1093/annonc/mdu126
24. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003 Jun;361(9373):1927-34.
25. Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer. 2011 Jan;117(2):276-82. doi: http://dx.doi.org/10.1002/cncr.25429
26. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep;62(3):523-33. doi: http://dx.doi.org/10.1016/j.eururo.2012.05.048
27. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb;67(2):241-9. doi: http://dx.doi.org/10.1016/j.eururo.2014.09.007
28. Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93. doi: http://dx.doi.org/10.1002/cncr.29387
29. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004 Feb;171(2 Pt 1):561-9. doi: http://dx.doi.org/10.1097/01.ju.0000090967.08622.33
30. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug;48(2):202-5.
31. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 Sep;352(9132):930-42.
32. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May;22(10):1797-806. doi: http://dx.doi.org/10.1200/JCO.2004.09.059
33. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006 Jan;42(1):50-4.
34. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun;32(18):1895-901. doi: http://dx.doi.org/10.1200/JCO.2013.53.2465
35. Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun;32(18):1889-94. doi: http://dx.doi.org/10.1200/JCO.2013.52.4785
36. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, et al. Downstaging and pathoanatomical outcome following neoadjuvant cisplatinum based combination chemotherapy for muscle-invasive bladder carcinoma: An analysis of selected patients from two combined randomised prospective Nordic trials. Urology. 2006;68(Suppl 5A):137. doi: http://dx.doi.org/10.1016/j.urology.2006.08.433
37. McLaren DB. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder. Clin Oncol (R Coll Radiol). 2005 Oct;17(7):503-7.
38. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov;31(8):1737-43. doi: http://dx.doi.org/10.1016/j.urolonc.2012.07.005
39. Yeshchina O, Badalato GM, Wosnitzer MS, Hruby G, RoyChoudhury A, Benson MC, et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology. 2012 Feb;79(2):384-90. doi: http://dx.doi.org/10.1016/j.urology.2011.10.050
40. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, et al. Bladder cancer. J Nat Compr Canc Netw. 2013;11:446-75. doi: http://dx.doi.org/10.6004 / jnccn.2013.0059
41. Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol. 2012 Nov-Dec;30(6):772-80. doi: http://dx.doi.org/10.1016/j.urolonc.2012.01.012
42. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001 May;19(9):2527-33.
43. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008 Dec;180(6):2384-8; discussion 2388. doi: http://dx.doi.org/10.1016/j.juro.2008.08.075
44. deVere White RW, Lara PN Jr, Goldman B, Tangen CM, Smith DC, Wood DP Jr, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun;181(6):2476-80; discussion 2480-1. doi: http://dx.doi.org/10.1016/j.juro.2009.01.115
45. Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005 Jun;65(6):1118-25. doi: http://dx.doi.org/10.1016/j.urology.2004.12.029
46. Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol. 2005 Jul;48(1):60-7. doi: http://dx.doi.org/10.1016/j.eururo.2005.03.025
47. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol. 1988 Oct;6(10):1590-6. doi: http://dx.doi.org/10.1200/JCO.1988.6.10.1590
48. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991 Mar;145(3):459-64.
49. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996 Feb;155(2):495-9.
50. Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992 Aug;148(2 Pt 1):302-6.
51. Bamias A, Deliveliotis Ch, Aravantinos G, Kalofonos Ch, Karayiannis A, Dimopoulos MA. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the hellenic cooperative oncology group. J Urol. 2004 Apr;171(4):1467-70.
52. Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012 Mar;23(3):695-700. doi: http://dx.doi.org/10.1093/annonc/mdr354
53. Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol. 2010;28:18. doi: http://dx.doi.org/10.1200/jco.2010.28.18_suppl.lba4518
54. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):76-86. doi: http://dx.doi.org/10.1016/S1470-2045(14)71160-X
55. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014 Jul;66(1):42-54. doi: http://dx.doi.org/10.1016/j.eururo.2013.08.033
56. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar;12(3):211-4. doi: http://dx.doi.org/10.1016/S1470-2045(10)70275-8
Information about authors:
Sukonko O.G. – Doctor of Medical Sciences, professor, director of N.N.Alexandrov National Cancer Centre of Belarus;
Polyakov S.L. – Doctor of Medical Sciences, head of the Oncourologic Pathology Laboratory, N.N.Alexandrov National Cancer Centre of Belarus;
Rolevich A.I. – Doctor of Medical Sciences, leading research officer of the Oncourologic Pathology Laboratory, N.N.Alexandrov National Cancer Centre of Belarus;
Zhegalik A.G. – oncologist-urologist of the oncourologic department, N.N.Alexandrov National Cancer Centre of Belarus.
Correspondence address: Republic of Belarus, 223040, Minsk district, agrogorodok Lesnoy, N.N. Alexandrov National Cancer Centre of Belarus, abdominal oncopathhology division, oncology department of hepatopancreatobiliary pathology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Alexander G. Zhegalik.
